unoprostone ophthalmic (Rx)

Brand and Other Names:Rescula
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic solution

  • 15%

Open-Angle Glaucoma

Indicated to lower IOP with open-angle glaucoma

1 gtt in affected eye(s) BID

Ocular Hypertension

Indicated to lower IOP with ocular hypertension

1 gtt in affected eye(s) BID

Retinitis Pigmentosa (Orphan)

Orphan designation for treatment of retinitis pigmentosa

Orphan sponsor

  • Sucampo Pharma Americas, Inc. 4520 East-West Highway Bethesda, MD 20814

<18 years: Safety and efficacy not established

Next:

Interactions

Interaction Checker

and unoprostone ophthalmic

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Burning/stinging (10-25%)

            Dry eyes (10-25%)

            Itching (10-25%)

            Increased length of eyelashes (10-25%)

            Conjunctival injection (10-25%)

            1-10%

            Abnormal vision (5-10%)

            Eyelid disorder (5-10%)

            Foreign body sensation (5-10%)

            Lacrimation disorder(5-10%)

            Decreased length of eyelashes (5-10%)

            Blepharitis (1-5%)

            Cataract (1-5%)

            Conjunctivitis (1-5%)

            Corneal lesion/erosion (1-5%)

            Ocular discharge/hemorrhage/pain (1-5%)

            Keratitis (1-5%)

            Irritation (1-5%)

            Photophobia (1-5%)

            Vitreous disorder (1-5%)

            Blurred vision (1-5%)

            Conjunctival hyperemia (1-5%)

            <1%

            Hyperpigmentation of the eyelid or iris and increased number of eyelashes

            Acute elevated IOP

            Color blindness

            Corneal deposits

            Corneal edema

            Corneal opacity

            Diplopia

            Optic atrophy

            Ptosis

            Retinal hemorrhage

            Visual field defect

            Postmarketing Reports

            Chemosis

            Dry mouth

            Nausea

            Vomiting

            Palpitations

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Cautions

            Increased pigmentation may occur due to increased melanin content in iris, eyelid periorbital tissues, and eyelashes

            May exacerbated active intraocular inflammation (eg, uveitis)

            Macular edema, including cystoid macular edema reported; caution in aphakic patients or pseudophakic patients with torn posterior lens capsule

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Unknown if distributed into human milk; use caution

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Decreases intraocular pressure by increasing outflow of aqueous humor through the trabecular meshwork

            Pharmacokinetics

            Absorbed: through cornea and conjunctival epithelium; minimal systemic absorption

            Half-Life: 14 min

            Peak Plasma: <1.5 ng/mL

            Metabolism: hydrolyzed by esterases to unoprostone free acid

            Excretion: urinary (as metabolites)

            Previous
            Next:

            Administration

            Ophthalmic Administration

            May use with other topical ophthalmic drugs to lower IOP; if 2 drugs are used, separate administration by at least 5 minutes

            Contains benzalkonium chloride, which may be absorbed by soft contact lenses; remove contact lenses before administration and wait at least 15 minutes after administration before reinserting contact lenses

            Avoid touching eyelids or surrounding areas with dropper bottle tip to minimize contaminating dropper tip and solution

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.